Status:
COMPLETED
A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Hyperlipidemia Combined
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Type IIb dyslipidemia is characterized by elevated triglycerides (TG ³ 150 mg/dL), and elevated LDL-C levels (³160 mg/dL). When in addition, HDL-C is low, the presence of the lipid triad, elevated TG ...
Eligibility Criteria
Inclusion
- Type IIb dyslipidemia.
Exclusion
- Known hypersensitivity to fibrates or ezetimibe. Pregnant or lactating women. Contra-indication to fenofibrate or ezetimibe.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT00349284
Start Date
January 1 2005
Last Update
September 3 2007
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 113
Charleroi, Belgium
2
Site 111
Comines, Belgium
3
Site 112
Couillet, Belgium
4
Site 115
Dessel, Belgium